Asparaginases: where do we go from here?
Ettinger
L J
LJ
Saint Peter's University Hospital, New Brunswick, New Jersey, USA.
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D001215:Asparaginase / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D002648:Child; D016974:Dickeya chrysanthemi / Q000201:enzymology; D004334:Drug Administration Schedule; D004926:Escherichia coli / Q000201:enzymology; D006801:Humans; D011092:Polyethylene Glycols / Q000627:therapeutic use; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*
D000970:Antineoplastic Agents; D011092:Polyethylene Glycols; C042705:pegaspargase; D001215:Asparaginase